PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: China - An overview • Social and economic conditions • Healthcare reforms • Healthcare infrastructure PART 06: Opportunities for global and local vendors • Local vendors • Global vendors PART 07: Pipeline analysis • AC-170 • DEXTENZA • Zerbaxa • Surotomycin • MK-3415A • Amikacin Inhale • CARBAVANCE • Eravacycline • Plazomicin • Delafloxacin • Solithromycin • VivaGel • Arikayce • Cadazolid • Ozenoxacin • TDT 067 • MOB-015 • 1334H • Auriclosene • EBI-005 • FST-100 • VT-1161 • Luliconazole solution, 10% • ME1111 • NP213 • HXP124 • SPL7013 • OPX-1 • AzaSite Xtra (ISV-405) • GD134 • PART 08: Market landscape • Pharmaceutical market in China • Market overview • Market size and forecast • Five forces analysis PART 09: Market segmentation by application PART 10: Antibacterial drugs market in China • MOA • Market size and forecast PART 11: Antiviral drugs market in China • Market size and forecast • Market segmentation by disease • Hepatitis C drugs market in China • Hepatitis B drugs market in China • HIV drugs market in China PART 12: Antifungal drugs market in China • Market size and forecast PART 13: Antiparasitic drugs market in China PART 14: Market drivers • Climatic changes • Increased exposure to chemicals and pollutants • Use of combination therapies • Increased prevalence of infectious diseases • Increase in awareness PART 15: Impact of drivers PART 16: Market challenges • Counterfeit drugs • Development of drug-resistant strains • Patent expiries and generic penetration • Decreased investments in research • Increased use of generics and CAMs PART 17: Impact of drivers and challenges PART 18: Market trends • Increase in collaborations and M&A • Emergence of IFN-free therapies • Increase in injection drug users PART 19: Vendor landscape • Competitive scenario • F. Hoffmann-La Roche • Gilead Sciences • GSK • Johnson & Johnson • Merck • Pfizer • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: China GDP 2010-2014 ($ trillions) Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP) Exhibit 04: Healthcare reforms in China Exhibit 05: New drug approval (NDA) review process in China Exhibit 06: New drug approval process in China Exhibit 07: Drug registration classification and requirements in China Exhibit 08: Infectious diseases treatment market in China: Pipeline portfolio Exhibit 09: Pharmaceutical market in China 2015-2020 ($ billions) Exhibit 10: China pharmaceutical market overview: SWOT analysis Exhibit 11: Share of infectious diseases market in pharmaceutical market in China 2015 Exhibit 12: Infectious disease treatment market in China 2015-2020 ($ billions) Exhibit 13: Venues for purchasing anti-infective drugs in China Exhibit 14: Five forces analysis Exhibit 15: Infectious disease treatment market in China segmentation by application Exhibit 16: Infectious disease treatment market in China segmentation by application 2015 Exhibit 17: Infectious disease treatment market in China segmentation by application 2020 Exhibit 18: Infectious disease treatment market in China segmentation by application 2015-2020 ($ billions) Exhibit 19: Infectious disease treatment market in China segmentation by application 2015-2020 (percentage) Exhibit 20: Infectious disease treatment market in China 2015-2020 Exhibit 21: YoY growth rate of Infectious disease treatment market in China segments 2015-2020 Exhibit 22: MOA of antibacterial drugs Exhibit 23: Antibacterial drugs market in China 2015-2020 ($ billions) Exhibit 24: Segmentation of antibacterial drugs market by chemical class Exhibit 25: Cephalosporin segmentation by generation of drugs Exhibit 26: Antibacterial drugs market in China revenue segmentation by chemical class Exhibit 27: Segmentation of antibacterial drugs market in China by drug origin Exhibit 28: Antiviral drugs market in China 2015-2020 ($ billions) Exhibit 29: Segmentation of antiviral drugs market in China by disease 2015 Exhibit 30: Segmentation of antiviral drugs market in China by disease 2020 Exhibit 31: Hepatitis C drugs market in China ($ billions) Exhibit 32: Hepatitis B drugs market in China 2015-2020 ($ millions) Exhibit 33: Segmentation of hepatitis B and C market based on MOA Exhibit 34: HIV drugs market in China ($ millions) Exhibit 35: HIV drugs market segmentation by drug class 2015 Exhibit 36: Antifungal drugs market in China 2015-2020 ($ millions) Exhibit 37: Antifungal drugs market in China segmentation by chemical class Exhibit 38: Antifungal drugs market segmentation by chemical class 2015 Exhibit 39: Antiparasitic drugs market in China ($ millions) Exhibit 40: Impact of drivers Exhibit 41: Antibiotic-resistant strains according to the period of development of resistance Exhibit 42: Impact of drivers and challenges Exhibit 43: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Pegasys (international) 2013-2015 ($ millions) Exhibit 44: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Tamiflu (international) 2013-2015 ($ millions) Exhibit 45: F. Hoffmann-La F. Hoffmann-La Roche: Key takeaways Exhibit 46: Gilead Sciences: YoY revenue and growth rate of Truvada (international markets) 2013-2015 ($ millions) Exhibit 47: Gilead Sciences: YoY revenue and growth rate of Atripla (international markets) 2013-2015 ($ millions) Exhibit 48: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions) Exhibit 49: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions) Exhibit 50: Gilead Sciences: Key takeaways Exhibit 51: GlaxoSmithKline: Key takeaways Exhibit 52: Johnson & Johnson: YoY revenue and growth rate of Olysio (International markets) 2013-3015 ($ millions) Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Prezista (international markets) 2013-3015 ($ millions) Exhibit 54: Johnson & Johnson: YoY revenue and growth rate of Edurant (international markets) 2013-3015 ($ millions) Exhibit 55: Johnson & Johnson: Key takeaways Exhibit 56: Merck: YoY revenue and growth rate of Cancidas (international markets) 2013-2015 ($ millions) Exhibit 57: Merck: YoY revenue and growth rate of Pegintron (international markets) 2013-2015 ($ millions) Exhibit 58: Merck: YoY revenue and growth rate of Isentress (international markets) 2013-2015 ($ millions) Exhibit 59: Merck: YoY revenue and growth rate of Invanz (international markets) 2013-2015 ($ millions) Exhibit 60: Merck: YoY revenue and growth rate of Noxafil (international markets) 2013-2015 ($ millions) Exhibit 61: Merck: YoY revenue of Cubicin (international markets) 2013-2015 ($ millions) Exhibit 62: Merck: Key takeaways Exhibit 63: Pfizer: YoY revenue and growth rate of Diflucan (emerging markets) 2013-2015 ($ millions) Exhibit 64: Pfizer: YoY revenue and growth rate of Suplerazon (emerging markets) 2013-2015 ($ millions) Exhibit 65: Pfizer: YoY revenue and growth rate of Tygacil (Emerging markets) 2013-2015 ($ millions) Exhibit 66: Pfizer: YoY revenue and growth rate of Vfend (emerging markets) 2013-2015 ($ millions) Exhibit 67: Pfizer: YoY revenue and growth rate of Zithromax (emerging markets) 2013-2015 ($ millions) Exhibit 68: Pfizer: YoY revenue and growth rate of Zyvox (emerging markets) 2013-2015 ($ millions) Exhibit 69: Pfizer: YoY revenue and growth rate of Tygacil (emerging markets) 2013-2015 ($ millions) Exhibit 70: Pfizer: Key takeaways

F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson & Johnson, Merck, Pfizer, Achaogen, Actelion, Adenovir Pharma, AstraZeneca, Bayer, Biocryst, Celsus therapeutics, Cempra, Eleven Biotherapeutics, Exoxemis, Ferrer International, Griffin Discoveries, Hexima, InSite Vision, Insmed Incorporated, KaloBios Pharmaceuticals, Lytix Biopharma, Meiji Seika Pharma, Melinta Therapeutics, Moberg Pharma, NanoViricides, Nektar, NicOx, NovaBay, NovaBiotics, Ocular Therapeutix, Panoptes Pharma, Paratek Pharmaceuticals, Polichem, PTC Therapeutics, RedHill, Shire, Starpharma Holding, Sun Pharma, Symbiomix, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Theravance Biopharma, Topica Pharmaceuticals, Vertex Pharmaceuticals, Viamet Pharmaceuticals.